Here are some sample widgets you could interact with from this dashboard:
The top 5 pharmaceutical companies garnered over $73 billion in oncology drugs sales in 2019, which compares with $38 billion sales seen in 2015. Roche leads the market with about $29 billion in worldwide oncology drugs sales, followed by Bristol-Myers Squibb, Merck, Johnson & Johnson, and Pfizer. Merck's oncology drugs sales grew at a stellar 116% CAGR between 2015 and 2019, 39x faster than the market leader Roche. Roche and Bristol-Myers Squibb generate roughly 50% of their total sales from oncology drugs.
Top 5 Pharmaceutical Companies Garnered Over $78 Billion In Oncology Drugs Sales In 2019Roche, Bristol-Myers Squibb, Merck, Johnson & Johnson, and Pfizer combined saw oncology drugs revenue grow at a CAGR of 17% from $38.5 billion in 2015 to $72.8 billion in 2019.
Total Oncology Drugs Sales
Change In Total Oncology Drugs Sales
Oncology Drugs Is One of The Most Important Segments For Pharmaceutical Companies, Accounting For Upto 50% of Their Total RevenueOf late, pharmaceutical companies have been focused on development of oncology drugs, given the kind of revenue these drugs generate. For Roche, almost 50% of its total sales used to come from oncology drugs, but that figure has now come down slightly. Similarly, for Bristol-Myers Squibb, oncology drugs account for around 50% of its total sales. The figure is 24% for Merck, 13% for Johnson & Johnson, and 17% for Pfizer. In fact, companies like Johnson & Johnson and Roche are involved in multiple businesses, including diagnostics, and healthcare products. The contribution of oncology drugs to these companies' pharmaceutical sales is even higher.
Roche Oncology Sales As % of Total Revenue
BMS Oncology Sales As % of Total Revenue
Merck Oncology Sales As % of Total Revenue
J&J Oncology Sales As % of Total Revenue
Pfizer Oncology Sales As % of Total Revenue
See our complete set of analyses for RocheJohnson & JohnsonBristol-Myers SquibbMerckPfizer